Atrial natriuretic peptide in patients with the syndrome of inappropriate antidiuretic hormone secretion and with diabetes insipidus.
To examine a possible role for atrial natriuretic peptide (ANP) in water and sodium metabolism disturbances associated with abnormal vasopressin (AVP) secretion, we measured plasma ANP concentrations in 15 patients with the syndrome of inappropriate antidiuretic hormone secretion (SIADH) and in 17 patients with central diabetes insipidus (DI). The mean plasma ANP concentration (30.2 +/- 10.4 pmol/L) in SIADH patients who had hyponatremia, plasma hypoosmolality, hyperosmolar urinary compared to plasma sodium levels, and increased plasma AVP levels relative to plasma osmolality was significantly higher than that in normal subjects (12.6 +/- 4.9 pmol/L), although there was a considerable individual variation in plasma ANP ranging from normal to clearly elevated levels (15.1-47.0 pmol/L). When hyponatremia was corrected by water restriction or demeclocycline administration, plasma ANP levels decreased significantly and fell into the normal range (12.5 +/- 4.3 pmol/L). DI patients who complained of polyuria and polydipsia and had hypoosmolar urine, normal or elevated plasma sodium concentrations, and decreased plasma AVP levels relative to plasma osmolality, on the other hand, had a significantly lower mean plasma ANP level (7.6 +/- 2.9 pmol/L) than normal subjects. There was, again, a considerable overlap between plasma ANP levels in individual DI patients (4.2-13.9 pmol/L) and those in normal subjects. Treatment with 1-desamino-8-D-arginine vasopressin resulted in a significant increase in the mean plasma ANP level (18.6 +/- 8.0 pmol/L). There were no significant correlations between plasma ANP and AVP levels in either group of patients. The results indicate that ANP secretion is modulated by changes in plasma volume consequent to abnormal AVP secretion, which may have a pathophysiological significance in maintaining volume homeostasis.
Kamoi
K
K
Department of Medicine, Nagaoka Red Cross Hospital, Niigata, Japan.
Ebe
T
T
Kobayashi
O
O
Ishida
M
M
Sato
F
F
Arai
O
O
Tamura
T
T
Takagi
A
A
Yamada
A
A
Ishibashi
M
M
D000293:Adolescent; D000328:Adult; D000368:Aged; D009320:Atrial Natriuretic Factor / Q000378:metabolism* / Q000502:physiology; D001810:Blood Volume / Q000187:drug effects; D003894:Deamino Arginine Vasopressin / Q000008:administration & dosage / Q000494:pharmacology; D003707:Demeclocycline / Q000008:administration & dosage / Q000494:pharmacology; D003919:Diabetes Insipidus / Q000378:metabolism*; D005260:Female; D006801:Humans; D007177:Inappropriate ADH Syndrome / Q000097:blood / Q000378:metabolism* / Q000652:urine; D008297:Male; D008875:Middle Aged; D011141:Polyuria / Q000378:metabolism; D012964:Sodium / Q000097:blood / Q000652:urine; D014667:Vasopressins / Q000378:metabolism* / Q000502:physiology; D014882:Water-Electrolyte Balance
D014667:Vasopressins; D003707:Demeclocycline; D009320:Atrial Natriuretic Factor; D012964:Sodium; D003894:Deamino Arginine Vasopressin